These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19635043)

  • 21. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
    Langley RG; Gupta AK; Cherman AM; Inniss KA
    J Cutan Med Surg; 2007; 11(3):99-122. PubMed ID: 17511926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological therapy for psoriasis.
    Clements SE; Abdul-Ghaffar S; Griffiths CE
    Br J Hosp Med (Lond); 2006 Apr; 67(4):184-7. PubMed ID: 16681304
    [No Abstract]   [Full Text] [Related]  

  • 24. Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies.
    van Lingen RG; Körver JE; van de Kerkhof PC; Berends MA; van Rens DW; Langewouters AM; Boezeman JB; Seyger MM; de Jong EM
    Br J Dermatol; 2008 Jul; 159(1):91-6. PubMed ID: 18476954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
    Bos WE; Thio HB; Neumann HA; van der Fits L; Prens EP
    Ned Tijdschr Geneeskd; 2006 May; 150(19):1065-70. PubMed ID: 16733982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological agents in the treatment of psoriasis.
    Tzu J; Krulig E; Cardenas V; Kerdel FA
    G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept.
    Tutrone WD; Saini R; Weinberg JM
    IDrugs; 2004 Jan; 7(1):45-9. PubMed ID: 14730466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.
    Julià M; Guilabert A; Lozano F; Suarez-Casasús B; Moreno N; Carrascosa JM; Ferrándiz C; Pedrosa E; Alsina-Gibert M; Mascaró JM
    JAMA Dermatol; 2013 Sep; 149(9):1033-9. PubMed ID: 24048425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy.
    Hamilton TK
    J Drugs Dermatol; 2008 Nov; 7(11):1089-93. PubMed ID: 19110745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab for the treatment of adults with psoriasis.
    Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
    Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with high-need psoriasis.
    Antoniou C; Dessinioti C; Vergou T; Stratigos AJ; Avgerinou G; Kostaki M; Katsambas A
    J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1413-20. PubMed ID: 20384690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding the new clinical landscape for psoriasis: a comparative review of biologics.
    Sauder DN; Mamelak AJ
    J Cutan Med Surg; 2004; 8(4):205-12. PubMed ID: 16091996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The role of biological drugs in the treatment of psoriasis, results from 9 randomized placebo-controlled trials].
    Kemény L; Brodszky V; Kárpáti K; Gulácsi L
    Orv Hetil; 2006 May; 147(21):981-90. PubMed ID: 16812973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment.
    Anstey AV; Kragballe K
    Int J Dermatol; 2006 Aug; 45(8):970-5. PubMed ID: 16911387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre.
    Warren RB; Brown BC; Lavery D; Ashcroft DM; Griffiths CE
    Br J Dermatol; 2009 Jan; 160(1):162-9. PubMed ID: 18808412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis.
    Saraceno R; Schipani C; Mazzotta A; Esposito M; Di Renzo L; De Lorenzo A; Chimenti S
    Pharmacol Res; 2008 Apr; 57(4):290-5. PubMed ID: 18400510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.